# Artivion to Report Earnings Thursday as Analysts Expect 6.8% Revenue Growth

> Artivion reports earnings Thursday after the bell, with analysts expecting 6.8% revenue growth, down from 18.4% a year earlier.

- Published: 2026-11-04T03:50:28+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-04/artivion-earnings-revenue-growth-expected
- Source: [FinancialContent Business Page](https://www.financialcontent.com/article/stockstory-2026-11-4-artivion-aort-to-report-earnings-tomorrow-here-is-what-to-expect)

## Key takeaways

- Artivion will announce earnings on Thursday after the bell, with analysts expecting revenue growth of 6.8% year on year.
- Artivion reported $125.8 million in revenue last quarter, up 11.3% year on year and ahead of analysts' expectations.
- Artivion completed its $175 million acquisition of Endospan Ltd. in May 2026, with up to $200 million in contingent payments tied to U.S. NEXUS commercial performance.

[Artivion](https://akta.pro/company-profiles/0000fk4/artivion) will report earnings on Thursday after the bell, with analysts expecting revenue growth of 6.8% year on year, according to the [FinancialContent Business Page](https://www.financialcontent.com/article/stockstory-2026-11-4-artivion-aort-to-report-earnings-tomorrow-here-is-what-to-expect). That would slow from the 18.4% increase the medical device company recorded in the same quarter last year.

## Artivion's Quarter and Analyst Expectations

Artivion beat analysts' revenue expectations last quarter, reporting revenues of $125.8 million, up 11.3% year on year. The report described it as a very strong quarter, with a beat of analysts' EPS estimates and full-year EBITDA guidance slightly topping analysts' expectations.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Artivion has missed Wall Street's revenue estimates multiple times over the last two years.

Among peers in the healthcare equipment and supplies segment, Merit Medical Systems delivered year-on-year revenue growth of 8.4%, beating analysts' expectations by 1.5%, and Intuitive Surgical reported revenues up 21.7%, topping estimates by 5.3%.

## Artivion's Endospan Deal and NEXUS Approval

Artivion completed its acquisition of Endospan Ltd. for $175 million, plus up to $200 million in contingent payments tied to U.S. NEXUS commercial performance, according to akta.pro [company records](https://akta.pro/company-data). The deal positions Artivion as the only company globally with a complete aortic arch solutions portfolio.

In April 2026, Artivion received FDA Pre-Market Approval for the NEXUS Aortic Arch System, the first off-the-shelf endovascular solution for aortic arch disease, including chronic aortic dissections in high-risk patients. In February 2026, the company released positive 1-year NEXUS TRIOMPHE IDE trial data, with 94% lesion-related survival and 91% freedom from disabling stroke, and 2-year AMDS PERSEVERE data showing zero distal anastomotic new entry tears and continued aortic remodeling.

Artivion's full-year 2026 guidance is $480-$496 million, representing 7-11% constant currency growth, lowered due to supply chain challenges and AMDS starter set sales shortfalls.

## Artivion's Path to Thursday's Report

On August 7, 2026, Yahoo reported that Artivion's Q2 2026 revenue of $125.8 million was up 9% year over year on a constant-currency basis, driven by 12% growth in stent grafts and 18% growth in On-X valves, though adjusted EBITDA margin declined to 21% due to higher R&D and Endospan-related costs.

Seeking Alpha reported on August 7, 2026, that Artivion's Q2 2026 EPS of $0.13 beat analyst estimates by $0.03 and revenue of $125.76 million represented 11.32% year-over-year growth and exceeded expectations by $5.74 million.

On May 11, 2026, PR Newswire reported that Ademi LLP was investigating possible securities fraud claims against Artivion, citing inaccurate statements about financials, operations, and prospects. On May 7, 2026, Artivion acknowledged that international stents sales were lower due to supply chain challenges.

## Artivion's Thursday Earnings Call

Artivion will announce its earnings results this Thursday after the bell, per the report.

## Companies in this story

- [Artivion company profile](https://akta.pro/company-profiles/0000fk4/artivion) · website: https://artivion.com

---
News for Agent · https://newsforagent.com/llms.txt